News

The American College of Rheumatology releases 2 new guidelines for treating patients with juvenile idiopathic arthritis.

Aspartyl-alanyl-diketopiperazine (Ampion), an intra-articular injection, works to regulate immune responses that are connected to pain, inflammation, and joint damage in patients with osteoarthritis of the knee.

In rheumatoid arthritis, a treat-to-target approach aims for remission or low disease activity within the first 3 months. However, investigators noted that improvements continued to increase throughout the 52-week period.

New recommendations were released by ACR and AAHKS regarding perioperative management of antirheumatic medications for patients with rheumatic diseases undergoing these procedures.

"For many years we lacked access to novel therapeutics in SLE and our outcomes frequently reflected this," stated Jack Arnold, MBBS, MRCP. "However, with new targeted therapies, we appear to be entering a new era where treatment decisions will require more nuanced thought."

The long-term success of any psoriatic arthritis treatment may be predictable as early as 3 months if a timely assessment and adjustment of disease management is prioritized.

“This dramatic change in healthcare delivery led to significant challenges amongst healthcare management teams, healthcare professionals as well as patients, especially during the early phases of implementation," investigators stated.

Results indicated that a brief methotrexate withdrawal after COVID-19 vaccine doses may improve immunogenicity in patients with rheumatoid arthritis.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 25, 2021.

Susan Shenoi, MBBS, MS, discusses the recent developments in pediatric rheumatology as well as new therapies and guidelines for treating juvenile idiopathic arthritis.

The American College of Rheumatology has recently updated its recommendations on COVID-19 booster vaccines. Test your knowledge of the latest advice on COVID-19 boosters and how they should be administered with this quiz.

Study provides supportive data to confirm the pathogenic role of NEU1 in proliferative lupus nephritis.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 18, 2021.

Up to 30% of patients with psoriasis eventually develop inflammatory synovio-entheseal (SE) inflammation.

Though psoriasis often precedes psoriatic arthritis, some studies have shown that the time to transition from psoriasis to PsA had not been fully explained by genetic factors alone.

Arthur Kavanaugh, MD, provides a year in review, including new developments, in rheumatoid arthritis as well as his thoughts on the use of biosimilars.

Arthur Kavanaugh, MD, explains the recent developments in psoriatic arthritis and spondyloarthritis, as well as what rheumatologists should look forward to in 2022.

Arthur Kavanaugh, MD, discusses the Rheumatology Winter Clinical Symposium, which runs from February 16 – 19.

Fatigue is commonly experienced by patients with rheumatoid arthritis, so how should patients experiencing it be managed? Take this quiz on managing fatigue in rheumatoid arthritis to test your knowledge.

Phase 3 of the FUTURE 5 trial further examined the efficacious effect that secukinumab had on patients with psoriatic arthritis.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 11, 2021.

In this Q&A, corresponding author Richard A Furie, MD, discussed the findings of his study comparing obinutuzumab with placebo for the treatment of proliferative lupus nephritis in combination with standard therapies.

According to the study, weight loss may be an effective strategy to prevent or treat pain in patients with hand osteoarthritis.

Using data from NHANES, researchers at the University of Chicago provide insight into associations of fat mass index and lean mass index on bone mineral density and how sex influences these associations.

“Food insecurity may increase an individual’s dependence on inexpensive energy-dense foods that lead to the development of chronic diseases that may affect mental health," investigators stated.

Upadacitinib monotherapy was effective in inhibiting structural joint damage progression in patients with rheumatoid arthritis who were MTX-naïve or had an inadequate response to MTX.

Some patients with rheumatoid arthritis will complain of fatigue, but do you know which patients are most at risk? Take this quiz on the risk factors for fatigue to find out.

Given the recent concerns regarding venous thromboembolic events in patients with rheumatic disease and pre-existing cardiovascular risk factors being treated with tofacitinib, investigators addressed the occurrence of VTE in patients with PsA.

The American College of Rheumatology (ACR) has published guidance regarding COVID-19 vaccination for patients with rheumatic diseases, with emphasis placed on supplemental and booster doses for patients with rheumatic disease.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 4, 2021.